Xiaodong Wang - Jun 10, 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
ONC
Transactions as of
Jun 10, 2025
Transactions value $
-$10,703,876
Form type
4
Date filed
6/12/2025, 05:39 PM
Previous filing
May 15, 2025
Next filing
Jun 25, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wang Xiaodong Director, Chair, Scientific Advisory Brd C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 2025-06-12 0001662982

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC Ordinary Shares Award $0 +98.7K +1.94% $0.00 5.18M Jun 10, 2025 Direct F1
transaction ONC American Depositary Shares Options Exercise $271K +41.8K $6.50 41.8K Jun 10, 2025 Direct F5
transaction ONC American Depositary Shares Sale -$758K -2.9K -6.95% $261.20 38.9K Jun 10, 2025 Direct F5, F6, F7
transaction ONC American Depositary Shares Sale -$4.16M -15.9K -40.86% $262.20 23K Jun 10, 2025 Direct F5, F6, F8
transaction ONC American Depositary Shares Sale -$4.24M -16.1K -70.03% $263.17 6.89K Jun 10, 2025 Direct F5, F6, F9
transaction ONC American Depositary Shares Sale -$1.79M -6.79K -98.55% $264.08 100 Jun 10, 2025 Direct F5, F6, F10
transaction ONC American Depositary Shares Sale -$26.5K -100 -100% $264.85 0 Jun 10, 2025 Direct F5, F6
holding ONC Ordinary Shares 1.03M Jun 10, 2025 See Footnote F2
holding ONC Ordinary Shares 3.95M Jun 10, 2025 See Footnote F3
holding ONC Ordinary Shares 50 Jun 10, 2025 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONC Share Option (Right to Buy) Award $0 +186K $0.00 186K Jun 10, 2025 Ordinary Shares 186K $20.26 Direct F11, F12
transaction ONC Share Option (Right to Buy) Options Exercise $0 -543K -100% $0.00 7 Jun 10, 2025 Ordinary Shares 543K $0.50 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F2 These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
F3 These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4 These securities are held by the spouse of the Reporting Person.
F5 Each American Depositary Share represents 13 Ordinary Shares.
F6 The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.66 to $261.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.66 to $262.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.66 to $263.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.66 to $264.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11 The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F12 These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F13 These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service.